Indian astronaut Shubhanshu Shukla, crew to enter quarantine ahead of Axiom-4 launch to International Space Station
Group Captain Shubhanshu Shukla and other crew members of the Axiom-4 (Ax-4) mission to the International Space Station (ISS) are entering quarantine ahead of the scheduled launch on June 8 from the National Aeronautics and Space Administration's (NASA) Kennedy Space Center in Florida.
The Indian astronaut and crew members were given a send-off by employees of Axiom Space Inc. on Sunday (May 25, 2025).
'Thank you so much for your contribution, I may not know you personally but I understand that it is each one of you that have contributed to this mission being a success and am sure it will be a success,' Group Captain Shukla, the pilot of the Ax-4 mission, told Axiom Space employees.
Also read | Experiments in Axiom mission to ISS to study if diabetics can stay in space
'The #Ax4 crew is on their way to quarantine. Before they go, Axiom Space employees came together to celebrate. Crew Send-off is a tradition that pays tribute to the dedication and tireless efforts of staff prior to the crew embarking on their mission. From #TeamAxiom, Godspeed #Ax4!' Axiom Space said in a post on social media platform X.
The other crew members on the mission are Commander Peggy Whitson of the U.S., Mission Specialist Sławosz Uznański-Wiśniewski of Poland, and Mission Specialist Tibor Kapu of Hungary. A SpaceX Falcon 9 rocket will launch the Ax-4 crew aboard a SpaceX Dragon spacecraft to the International Space Station from Launch Complex 39A at the Kennedy Space Center.
The Ax-4 crew will spend up to 14 days at the orbiting laboratory.
Group Captain Shukla, who is also one of the four astronaut-designates selected for the Indian Space Research Organisation's (ISRO) Gaganyaan mission, will be the first Indian astronaut to reach the ISS, and the first Indian in space after 40 years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
India.com
an hour ago
- India.com
India's Rs 548 crore Space Leap: Shukla rides the Falcon 9 to the ISS
On June 10, 2025, at 5:52 PM IST (8:22 AM EDT), Group Captain Shubhanshu Shukla will lift off to the International Space Station (ISS), becoming the first Indian astronaut since 1984 to undertake such a journey. As the pilot of Axiom Mission 4 (Ax-4), he will fly aboard a SpaceX Crew Dragon spacecraft, launched on a Falcon 9 rocket from NASA's Kennedy Space Center in Florida. After approximately 28 hours of travel, the crew is expected to dock with the ISS by 10:00 PM IST on June 11, 2025. Shukla joins an elite international crew: Commander Peggy Whitson (USA, Axiom Space), and Mission Specialists Sławosz Uznański-Wiśniewski (Poland, ESA) and Tibor Kapu (Hungary, Hunor Programme). The team will spend up to 14 days aboard the ISS, conducting over 60 scientific experiments from 31 countries, including seven from India, such as research on plant growth in microgravity, muscle regeneration, and tardigrade resilience. Born on October 10, 1985, in Lucknow, Shukla is a decorated Indian Air Force test pilot with over 2,000 flight hours. He has undergone rigorous astronaut training in Russia and at SpaceX facilities in the US, and will assist in spacecraft navigation, docking, and emergency procedures during the mission. But beyond his technical role, Shukla carries India's cultural pride into space—bringing along items designed by National Institute of Design (NID) students, performing yoga in microgravity, sharing Indian delicacies like mango nectar and moong dal halwa, and planning live interactions with Indian school children and possibly Prime Minister Narendra Modi. SpaceX has revolutionized space travel economics. While NASA pays around $55 million per seat under its commercial crew program, private clients like Axiom Space are charged $52–55 million per seat, excluding stay-related fees. NASA charges $35,000 per night per astronaut for use of the ISS. India's investment for Shukla's mission seat is around ₹548 crore (approximately $65 million), while the total private mission cost per astronaut can go up to $100 million, including training and logistics. In comparison, Russia's Soyuz costs around $80–86 million per seat, Boeing's Starliner costs about $90 million, and the now-retired Space Shuttle had a cost of approximately $170 million per astronaut. For reference, cargo missions on SpaceX's Dragon cost anywhere between $21,000 and $89,000 per kg, while human missions are far costlier due to added life support and safety systems. Shukla's mission is more than just a spaceflight—it's a symbol of India's return to human space exploration. He carries a special swan named 'Joy', representing wisdom (India), resilience (Poland), and grace (Hungary). The scientific experiments onboard are expected to contribute to India's ambition of establishing a space station by 2035 and support its moon mission goals set for 2047. This mission also strengthens international space ties, especially between India and the US, following commitments made during PM Modi's 2023 visit. In every sense, Group Captain Shubhanshu Shukla's journey aboard the human-rated Falcon 9 rocket is a giant leap for India—both in science and symbolism. With his successful flight, India not only rekindles its human spaceflight legacy after four decades but also sets the stage for greater roles in global space partnerships, cutting-edge research, and inspiration for the next generation of Indian scientists, engineers, and dreamers. —E.O.M (Girish Linganna is an award-winning science communicator and a Defence, Aerospace & Geopolitical is the Managing Director of ADD Engineering Components India Pvt. Ltd., a subsidiary of ADD Engineering GmbH, Germany )
Time of India
2 hours ago
- Time of India
'I'll miss earth': Shubhanshu Shukla reflects on space, family & mystery of his astronaut number
As Group Captain prepares for launch aboard Axiom Mission 4 (Ax-4), he finds himself not swept up by emotion but rooted in precision. In this final phase — quarantine before liftoff — every minute mirrors the rhythms of orbit. Tired of too many ads? go ad free now Yet beneath the discipline, a quieter current runs: anticipation of the unknown, the emotion of leaving Earth behind, and a playful curiosity about the number he'll earn in humanity's celestial roll call. Late on Tuesday, Shukla answered three specific questions from TOI, where he spoke about the mental space he's in, what excites him most about the days ahead, and what he quietly longs for when the mission ends. Excerpts: You're so close to lift-off. How exactly do you feel? We are pretty close to launching now. But if you ask me how I feel at this moment, I'd say I'm focused on sticking to the schedule and getting everything done as planned. Even here in quarantine, the training is quite intense—it's designed to reflect the pace and structure of our time aboard the station. So, no big emotions just yet. We're very busy preparing for the mission. As Peggy [Whitson] told me, it's probably on the dry dress day — when we go to the launchpad for rehearsal — that we'll really start to feel the gravity of it all. What's the most exciting part about going to space? Have you planned anything right after docking? Everything is going to be tightly scripted. From the minute we dock, right up until we go to sleep, each task is scheduled on our timeline. It's all orchestrated, and we'll be busy performing those activities. But there is something I'm particularly excited about. Once you enter space, every astronaut is given a traveller number—like a unique ID marking your place in the list of humans who've been to orbit. Tired of too many ads? go ad free now That information is currently with my commander, Peggy, and she's keeping it a secret for now! So I'm really looking forward to finding out what number I'll be. What's the first thing you plan to do when you return to your family? Honestly, I haven't planned anything specific yet. I imagine being in orbit for 14 days will be a truly novel experience—one that comes with a mix of emotions. Leaving Earth feels a lot like leaving home. You miss it. You miss your people. So yes, there's already a sense of longing. I haven't thought about exactly what I'll do when I return, but I'm sure that after two weeks up there, I'll know what matters most to me. I'll have a better idea of what I want to do the moment I see them again.
